Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Encysive Pharmaceuticals
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) as compared to placebo in the treatment of patients with PAH. A cohort of patients will be randomized to usual treatment with Tracleer® (bosentan) for observational comparisons of safety and efficacy.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a current diagnosis of symptomatic PAH classified by one of the following:
1. primary pulmonary hypertension (PPH) - also known as idiopathic pulmonary arterial hypertension (IPAH);
2. PAH associated with connective tissue diseases;
3. PAH associated with one of the following congenital heart defects:
1. repaired ASD, VSD or PDA greater than one year post-operative
2. un-repaired secundum ASD (with resting oxygen saturation greater than 88 percent in room air measured by oximeter)
World Health Organization (WHO) functional class II, III, IV
Greater than 12 and less than 75 years of age
Women of childbearing potential must be using two forms of medically acceptable contraception (at least one barrier method)
Have a cardiac catheterization within 6 months before study entry that shows the following values:
1. mean pulmonary artery pressure (PAPm) greater than 25 mmHg (at rest),
2. pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure less than 15 mmHg, and
3. pulmonary vascular resistance (PVR) greater than 3 mmHg/L/min.
You may not be if
Portal hypertension or chronic liver disease
ALT or AST levels greater than 1.5 times the upper limit of normal at the Screening Visit
Contraindication to treatment with an endothelin receptor antagonist
Recent history of abusing alcohol or illicit drugs
Chronic renal insufficiency
Pregnant or breastfeeding
Atrial septostomy within 30 days before study entry
Previous failure on bosentan because of safety concerns of the lack of clinical response
